Tacrolimus

May 13, 2020

COVID-19 Prompts New Home Test for Kids with Organ Transplants

Nov 12, 2019

Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2019

Oct 30, 2019

Veloxis Increases Outlook for 2019 Based on Continued Strong Performance

Oct 22, 2019

Organ Transplant Immunosuppressant Drugs Market Worth $5.88 Billion by 2026: Grand View Research, Inc.

Jul 22, 2019

Veloxis Revises Outlook for 2019 Based on Strong Performance

Mar 18, 2019

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Nov 14, 2018

Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights

Oct 10, 2018

Veloxis to Present at the Jefferies 2018 London Healthcare Conference

Apr 20, 2018

FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®

Mar 28, 2018

Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®

Mar 07, 2018

Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®

Nov 09, 2017

Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast - 2025

Sep 04, 2017

Dermatological Drugs Market Forecast 2017-2027

Jun 06, 2017

Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China